Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
05 Nov 2024
Historique:
medline: 31 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: ppublish

Résumé

The use of lipid nanoparticles (LNPs) for therapeutic RNA delivery has gained significant interest, particularly highlighted by recent milestones such as the approval of Onpattro and two mRNA-based SARS-CoV-2 vaccines. However, despite substantial advancements in this field, our understanding of the structure and internal organization of RNA-LNPs -and their relationship to efficacy, both in vitro and in vivo- remains limited. In this study, we present a coarse-grained molecular dynamics (MD) approach that allows for the simulations of full-size LNPs. By analyzing MD-derived structural characteristics in conjunction with cellular experiments, we investigate the effect of critical parameters, such as pH and composition, on LNP structure and potency. Additionally, we examine the mobility and chemical environment within LNPs at a molecular level. Our findings highlight the significant impact that LNP composition and internal molecular mobility can have on key stages of LNP-based intracellular RNA delivery.

Identifiants

pubmed: 39475644
doi: 10.1073/pnas.2404555121
doi:

Substances chimiques

Lipids 0
Lipid Nanoparticles 0
RNA 63231-63-0
Liposomes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2404555121

Déclaration de conflit d'intérêts

Competing interests statement:All authors are current employees of Bayer AG or Nuvisan ICB GmbH.

Auteurs

Adiran Garaizar (A)

Drug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.
Computational Life Science, Bayer Crop Science, Monheim am Rhein 40789, Germany.

David Díaz-Oviedo (D)

Drug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.

Nina Zablowsky (N)

Lead Discovery, Nuvisan Innovation Campus Berlin, Berlin 13353, Germany.

Sami Rissanen (S)

Chemical and Pharmaceutical Development, Bayer Pharmaceuticals, Turku 20210, Finland.

Johannes Köbberling (J)

Drug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.

Jiawei Sun (J)

Chemical and Pharmaceutical Development, Bayer Pharmaceuticals, Berlin 13353, Germany.

Christoph Steiger (C)

Chemical and Pharmaceutical Development, Bayer Pharmaceuticals, Berlin 13353, Germany.

Patrick Steigemann (P)

Lead Discovery, Nuvisan Innovation Campus Berlin, Berlin 13353, Germany.

Florian A Mann (FA)

Chemical and Pharmaceutical Development, Bayer Pharmaceuticals, Berlin 13353, Germany.

Katharina Meier (K)

Drug Discovery Sciences, Bayer Pharmaceuticals, Wuppertal 42113, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH